Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Strokes are affecting approximately 1.8 million people annually
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
CSPC will receive an upfront payment of $100 million from AstraZeneca
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
The inspection conducted by EDQM at its Visakhapatnam facility
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Subscribe To Our Newsletter & Stay Updated
